ERASCA LEAD PLAINTIFF DEADLINE AUGUST 10th: Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors with Large Losses to Contact the Firm Regarding their Rights

Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors with Large Losses to Contact the Firm Regarding their Rights

If you purchased or acquired Erasca common stock during the period from January 14, 2025 through April 26, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected] or by telephone at (212) 355-4648.

What’s Happening? Bragar Eagel & Squire, P.C ., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS) in the United States District Court for the Southern District of California on behalf of all persons and entities who purchased or otherwise acquired Erasca common stock during the period from January 14, 2025 through April 26, 2026 , both dates inclusive (the “Class Period”). Investors have until August 10, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

What are the Allegation Details? The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts, including allegations that: (1) ERAS-0015’s preclinical data was based on improper comparisons to Revolution Medicines, Inc. and placed Erasca at risk of violating patent and trade secret protections; and (2) based on the foregoing, Defendants lacked a reasonable basis for their positive statements related to ERAS-0015.

On April 28, 2026, Erasca disclosed that it had received a letter from Revolution Medicines alleging that Erasca’s ERAS-0015—a Phase 1 oral pan-RAS molecular glue inhibitor designed to target cancers—infringes a Revolution patent and is associated with alleged trade secret misappropriation. Following this disclosure, Erasca’s share price declined by $9.25 per share, or approximately 48%, falling from $19.15 per share on April 27, 2026 to close at $9.90 per share on April 28, 2026.

What are my Next Steps? If you purchased or otherwise acquired Erasca shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected] , telephone at (212) 355-4648, or by filling out this contact form . There is no cost or obligation to you.